Skip to main
HIMS
HIMS logo

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 29%
Buy 6%
Hold 47%
Sell 12%
Strong Sell 6%

Bulls say

Hims & Hers Health Inc. demonstrated robust financial performance with a total revenue growth of 95.1% year-over-year, driven by a significant increase in online revenue, which rose 98.3% to $470.8 million. The company experienced substantial subscriber growth, adding 182,000 in the quarter, bringing the total to 2.2 million, which represents a 45.0% increase year-over-year. Management's expectation for the weight loss business to constitute approximately 30% of FY25 revenue, alongside a growing trend towards premium personalized offerings, highlights the company’s strategic positioning for continued growth and profitability.

Bears say

Hims & Hers Health Inc is facing significant headwinds due to rising costs and increased competition from venture-backed companies that can undercut pricing, threatening the company’s market share and squeezing profit margins. Additionally, the company experienced a decline in gross margins in Q4, attributed to a less favorable product mix and lower pricing on certain offerings, which, combined with higher marketing costs, may further strain operating margins. The current valuation appears stretched at more than 4x EV/Sales based on management's guidance, leaving little room for favorable adjustment in the stock price following an approximate 18% drop after hours.

HIMS has been analyzed by 17 analysts, with a consensus rating of Hold. 29% of analysts recommend a Strong Buy, 6% recommend Buy, 47% suggest Holding, 12% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 17 analysts, HIMS has a Hold consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.